IN2014DN08672A - - Google Patents

Info

Publication number
IN2014DN08672A
IN2014DN08672A IN8672DEN2014A IN2014DN08672A IN 2014DN08672 A IN2014DN08672 A IN 2014DN08672A IN 8672DEN2014 A IN8672DEN2014 A IN 8672DEN2014A IN 2014DN08672 A IN2014DN08672 A IN 2014DN08672A
Authority
IN
India
Prior art keywords
inhalation
pharmaceutically acceptable
pharmaceutical composition
provides
present
Prior art date
Application number
Other languages
English (en)
Inventor
Ruiz Sandrine Allain
Nunez Beatriz Seoane
Miquel Serra Gonzalo De
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN08672(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of IN2014DN08672A publication Critical patent/IN2014DN08672A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IN8672DEN2014 2012-05-31 2013-05-30 IN2014DN08672A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382221.5A EP2668941A1 (fr) 2012-05-31 2012-05-31 Nouveau dosage et formulation d'abediterol
US201261660003P 2012-06-15 2012-06-15
PCT/EP2013/061181 WO2013178742A1 (fr) 2012-05-31 2013-05-30 Nouvelle forme de dosage et nouvelle formulation d'abéditérol

Publications (1)

Publication Number Publication Date
IN2014DN08672A true IN2014DN08672A (fr) 2015-05-22

Family

ID=46317311

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8672DEN2014 IN2014DN08672A (fr) 2012-05-31 2013-05-30

Country Status (29)

Country Link
US (2) US20150140099A1 (fr)
EP (2) EP2668941A1 (fr)
JP (1) JP6272836B2 (fr)
KR (2) KR20180104197A (fr)
CN (1) CN104394852A (fr)
AR (1) AR091233A1 (fr)
AU (1) AU2013269565B2 (fr)
BR (1) BR112014029735A2 (fr)
CA (1) CA2871358C (fr)
CL (1) CL2014003286A1 (fr)
CO (1) CO7141434A2 (fr)
CR (1) CR20140540A (fr)
DO (1) DOP2014000271A (fr)
EA (1) EA201401354A1 (fr)
EC (1) ECSP14028814A (fr)
HK (1) HK1203149A1 (fr)
IL (1) IL235831B (fr)
IN (1) IN2014DN08672A (fr)
MX (1) MX2014014350A (fr)
MY (1) MY184654A (fr)
NI (1) NI201400139A (fr)
NZ (1) NZ701261A (fr)
PE (1) PE20150171A1 (fr)
PH (1) PH12014502662A1 (fr)
SG (3) SG10201609119VA (fr)
TW (1) TWI610690B (fr)
UY (1) UY34838A (fr)
WO (1) WO2013178742A1 (fr)
ZA (1) ZA201407405B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
WO2014007781A2 (fr) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation
MA40027A (fr) * 2014-06-18 2015-12-23 Cipla Ltd Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
WO2019142214A1 (fr) * 2018-01-19 2019-07-25 Cipla Limited Composition pharmaceutique comprenant du tiotropium destinée à être inhalée
WO2019226697A1 (fr) 2018-05-22 2019-11-28 C.R. Bard, Inc. Système de cathétérisme et procédés pour son utilisation
CN112566550B (zh) 2018-08-10 2024-10-22 C·R·巴德股份有限公司 自动化尿排出量测量系统及其方法
US12083261B2 (en) 2020-06-05 2024-09-10 C. R. Bard, Inc. Automated fluid output monitoring
US12055249B2 (en) 2020-07-21 2024-08-06 C. R. Bard, Inc. Automatic fluid flow system with retractable connection
US12558474B2 (en) 2020-11-19 2026-02-24 C. R. Bard, Inc. Dynamic pressure response system
US12408853B2 (en) 2020-12-17 2025-09-09 C. R. Bard, Inc. Smart bag to measure urine output via catheter
US12364423B2 (en) 2020-12-21 2025-07-22 C. R. Bard, Inc. Automated urinary output-measuring systems and methods
US11931151B2 (en) 2020-12-22 2024-03-19 C. R. Bard, Inc. Automated urinary output measuring system
US12246146B2 (en) 2020-12-23 2025-03-11 C. R. Bard, Inc. Automated weight based fluid output monitoring system
WO2022182794A1 (fr) 2021-02-23 2022-09-01 C. R. Bard, Inc. Systèmes et méthodes de surveillance de la vessie non invasive et à auto-apprentissage
US12667479B2 (en) 2021-07-23 2026-06-30 C. R. Bard, Inc. Urine output collection and monitoring systems, devices, and methods
US12446813B2 (en) 2021-08-23 2025-10-21 C. R. Bard, Inc. Automated urine output system for attachment to hospital bed
WO2025151671A1 (fr) * 2024-01-12 2025-07-17 Texas Tech University System Compositions et méthodes de traitement de l'obésité induite par un régime alimentaire et de troubles métaboliques associés

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
EP0069715B1 (fr) 1981-07-08 1986-11-05 Aktiebolaget Draco Inhalateur de poudre
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (fr) 1990-08-11 1992-03-05 Fisons Plc Dispositif d'inhalation
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
JP2924924B2 (ja) 1992-12-18 1999-07-26 シェリング・コーポレーション 粉末薬物のための吸入器
PL182198B1 (en) 1995-06-21 2001-11-30 Asta Medica Ag Pharmaceutic powder holding container with integrated measuring device and powdered
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2540005A1 (fr) * 2003-09-26 2005-04-07 Schering Corporation Traitement de maladie pulmonaire
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1616592B9 (fr) 2004-07-16 2011-02-02 Almirall, S.A. Inhalateur pour l'administration des composés pharmaceutiques en poudre, et cartouche de poudre utilisée avec cet inhalateur
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2100598A1 (fr) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2196465A1 (fr) 2008-12-15 2010-06-16 Almirall, S.A. Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (fr) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one pour le traitement de la fonction pulmonaire
EP2221297A1 (fr) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one et son utiisation dans le traitement de maladies des voies respiratoires

Also Published As

Publication number Publication date
TWI610690B (zh) 2018-01-11
TW201347789A (zh) 2013-12-01
MY184654A (en) 2021-04-14
JP2015519356A (ja) 2015-07-09
EP2854771A1 (fr) 2015-04-08
SG11201407110QA (en) 2014-12-30
DOP2014000271A (es) 2015-02-27
CO7141434A2 (es) 2014-12-12
SG10201913424SA (en) 2020-03-30
NI201400139A (es) 2015-12-10
EA201401354A1 (ru) 2015-05-29
ECSP14028814A (es) 2015-12-31
HK1203149A1 (en) 2015-10-23
US20160303108A1 (en) 2016-10-20
US20150140099A1 (en) 2015-05-21
PH12014502662A1 (en) 2015-02-02
AU2013269565B2 (en) 2017-07-20
PE20150171A1 (es) 2015-01-31
CA2871358C (fr) 2020-09-29
IL235831A0 (en) 2015-01-29
SG10201609119VA (en) 2016-12-29
JP6272836B2 (ja) 2018-01-31
ZA201407405B (en) 2015-11-25
EP2668941A1 (fr) 2013-12-04
CR20140540A (es) 2015-01-16
BR112014029735A2 (pt) 2017-06-27
WO2013178742A1 (fr) 2013-12-05
AU2013269565A1 (en) 2014-10-30
CA2871358A1 (fr) 2013-12-05
KR20150018526A (ko) 2015-02-23
CL2014003286A1 (es) 2015-02-20
CN104394852A (zh) 2015-03-04
KR20180104197A (ko) 2018-09-19
MX2014014350A (es) 2015-03-03
NZ701261A (en) 2016-08-26
AR091233A1 (es) 2015-01-21
IL235831B (en) 2020-09-30
UY34838A (es) 2014-03-31

Similar Documents

Publication Publication Date Title
NZ701261A (en) Novel dosage form and formulation of abediterol
UA101653C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
MX382999B (es) Polvos pulmonares de ultra baja densidad
WO2014016548A3 (fr) Composition pharmaceutique
EP2682108A3 (fr) Inhalateurs de poudre sèche comprenant un support autre que le lactose et un composant ternaire
EP2682097A3 (fr) Inhalateurs de poudre sèche comprenant un support autre que le lactose
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
IN2014MN02133A (fr)
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol
WO2019098969A3 (fr) Compositions de poudre sèche à inhaler
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TH1401007107A (th) รูปฟอร์มขนาดใช้ยา และ สูตรผสมใหม่ของเอบีไดเทอรอล
GR1008468B (el) Μιγμα σισπλατινης σε μορφη λεπτοκοκκης εισπνεομενης ξηρας σκονης
BR112014028864A2 (pt) dosagem e formulação
TN2011000121A1 (en) Inhalable particles comprising tiotropium